First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report

Eur J Gastroenterol Hepatol. 2008 May;20(5):472-3. doi: 10.1097/MEG.0b013e3282f16411.

Abstract

We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / secondary
  • Fatal Outcome
  • HIV Infections / complications*
  • HIV-1*
  • Hepatitis B, Chronic / complications
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / drug therapy*
  • Male
  • Middle Aged

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab